

Warsaw, 19 July 2023

**PRICE INQUIRY NO. SEMA/8/PR22389/2023  
being conducted as a market assessment study**

In connection with the implementation of the project titled "Design and development of an innovative solution - a generic drug belonging to the class of GLP-1 receptor agonists in the treatment of type 2 diabetes", financed from the state budget funds from the Medical Research Agency, WZA Polfa Warszawa S.A. requests that you submit bids concerning **the purchase and supply of the reference product Ozempic** solution for injection in accordance with the order specification below.

### **I. NAME AND ADDRESS OF THE CUSTOMER**

**Warszawskie Zakłady Farmaceutyczne Polfa S.A.**  
ul. Karolkowa 22/24  
01-207 Warszawa

### **II. CONTRACT AWARD PROCEDURE**

- II.1.** This contract is not subject to the provisions of the Public Procurement Law of 11 September 2019 (consolidated text: Journal of Laws of 2019, item 2019).
- II.2.** The procedure is being conducted as an intentional and cost-efficient market assessment study while respecting the following rules:
- 1) achieving the best possible outcomes using the available measures;
  - 2) to choose the best possible means and methods to meet the pre-defined objectives;
  - 3) to ensure transparency, fair competition and equal treatment of contractors.

### **III. DESCRIPTION OF THE OBJECT OF THE PRICE INQUIRY**

- III.1.** The subject matter of the Request for Quotation is the purchase and supply of the reference product Ozempic solution for injection in the quantity specified below.
- III.2. CPV CODE 33600000-6 Pharmaceutical products**
- III.3.** Scope of the Price Inquiry:
- PART 1. Ozempic 2 mg/1.5 mL (1.34 mg/mL)** solution for injection in a pre-filled pen containing 0.5 mg of Semaglutide in a single dose – 30 units from any production batch plus 3 units from three separate production batches, i.e. a total of 39 units.
- PART 2. Ozempic 4 mg/3 mL (1.34 mg/mL)** solution for injection in a pre-filled pen containing 1 mg of Semaglutide in a single dose – 63 units from any production batch plus 3 units from three separate production batches, i.e. a total of 72 units.
- PART 3. Ozempic 8 mg/3 mL (2.68 mg/mL)** solution for injection in a pre-filled pen containing 2 mg of Semaglutide in a single dose – 53 units from any production batch plus 3 units from three separate production batches, i.e. a total of 62 units.
- III.4.** The shelf life of the product should be at least **19 (say: nineteen) months** from the order delivery date.
- III.5.** The Customer accepts bids for parts of the order.

**III.6.** The Customer does not accept equivalent products.

**III.7.** Option right:

Basic order specified in section III.1. may be increased but by no more than 10 units for each Part 1), 2), 3).

#### IV. PRICE INQUIRY DELIVERY SITE AND DATE

**IV.1.** Deadline for the performance of the subject matter of the Request for Quotations: **6 weeks from the date of placing the order** by the Customer. Bids with a contract delivery period exceeding 6 weeks will be rejected.

**IV.2.** The subject of the Price Inquiry must be delivered at the Seller's expense to the Buyer's offices at: Warszawskie Zakłady Farmaceutyczne Polfa Spółka Akcyjna, ul. Barska 31, 02-315 Warszawa.

#### V. REQUIREMENTS FOR CONTRACTORS

**V.1.** The contract may be awarded to Contractors who, when carrying out sales and delivery of materials constituting the object of the procedure, operate in accordance with the Pharmaceutical Law Act of 6 September 2001 (Journal of Laws of 2008 No. 45, item 271, as amended) and are not involved in the so-called reverse drug distribution chain.

**V.2** Entities for which the following circumstances occur are excluded from the procedure:

- a) as described in Article 7(1) of the Act of 13 April 2022 on Special Measures to Counteract Support for the Aggression against Ukraine and to Protect National Security;
- b) as described in Article 5k of the Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine.

Method of verification of grounds/lack of grounds for exclusion:

*The verification shall take place on the basis of the Bidder's declaration.*

#### VI. CONTRACT AWARD CRITERIA

**VI.1.** The following criteria will be used by the Customer for the assessment of bids:

– net price of the subject matter of the contract – 100%

$$P_C = \frac{C_N}{C_B} * 100 \text{ points}$$

The score ( $P_C$ ) for the Total Net Price will be calculated as follows:

where:

- |       |   |   |
|-------|---|---|
| $P_C$ | - | score for the Total Net Price                         |
| $C_N$ | - | the lowest total net price based on non-rejected bids |
| $C_B$ | - | total net price of the bid under evaluation           |

Bids with the price given in a currency other than PLN will be converted to PLN at the average exchange rate of the National Bank of Poland as at the final date for the submission of bids.

The price will be given score separately for each part of the contract.

**VI.2.** The maximum score that can be awarded to Bidder is 100 points, separately for each part of the procedure. Calculations will be made to two decimal places.

## VII. PLACE AND DEADLINE FOR SUBMISSION OF BIDS

**VII.1.** The final deadline for submitting bids is 26.07.2023

– in electronic format (a scan of a signed document or a document signed with a qualified signature) to the following email address: [barbara.wendolowska@polpharma.com](mailto:barbara.wendolowska@polpharma.com)

**VII.2.** A bid will be considered to have been properly submitted if a complete bid is delivered to the above email address within the time limit stipulated in this section.

**VII.3.** No bids submitted past the submission deadline will be considered.

## VIII. PREPARATION OF BIDS

**VIII.1.** The Bidder should draw up one bid using the bid form attached as Appendix 1 hereto.

**VIII.2.** Bids may be modified or withdrawn prior to the end of the time limit for the submission of bids.

**VIII.3.** Bidders are required to carefully read the information contained in the Price Inquiry.

**VIII.4.** For any matters related to this Price Inquiry, please contact the Customer, e-mail: [barbara.wendolowska@polpharma.com](mailto:barbara.wendolowska@polpharma.com)

## VII. ADDITIONAL INFORMATION

**VII.1.** Any costs and expenses incurred in connection with the preparation and submission of bids are to be paid by the respective Bidders.

**VII.2.** Until the end of the time limit for the submission of bids, the Customer reserves the right to amend or add new information to this Price Inquiry.

## VIII. LIST OF APPENDICES

The following appendices are attached to this Price Inquiry:

| Appendix number | Appendix title |
|-----------------|----------------|
| Appendix 1      | Bid Form       |
|                 |                |

Appendix 1 to the Price Inquiry No. SEMA/8/PR22389/2023

**BID FORM**

**Bidder:**

|   |  |
|---|--|
| <b>Name / Company</b>   |  |
| <b>Registered office/place of residence/address of the principal place of business</b>    |  |
| <b>Email address for the Customer to send correspondence related to the Price Inquiry</b> |  |
| <b>NIP [Taxpayer ID Number]</b>   |  |
| <b>REGON [Statistical ID Number]</b>  |  |
| <b>Phone number</b>   |  |
| <b>Contact person for the Customer</b>  |  |

We offer the delivery of the subject of the contract for the **purchase and delivery of a reference product OZEMPIC**, in accordance with the terms of the Price Inquiry for the following **price**:

| <b>Part</b> | <b>Subject of the Price Inquiry</b> | <b>Units</b> | <b>Quantity</b> | <b>Net PLN/EUR/USD price* per IU</b> | <b>Total net value PLN/EUR/USD*</b> | <b>Total gross value PLN/EUR/USD*</b> | <b>Delivery time [number of weeks from the date of placing the order]</b> | <b>Shelf life calculated from the date of product delivery</b> |
|-------------|-------------------------------------|--------------|-----------------|--------------------------------------|-------------------------------------|---------------------------------------|---|--|
| <b>1</b>    |                                     |              |                 |                                      |                                     |                                       |   |  |
| <b>2</b>    |                                     |              |                 |                                      |                                     |                                       |   |  |
| <b>3</b>    |                                     |              |                 |                                      |                                     |                                       |   |  |

**The due date for invoices is within ..... days**

**The Bidder has the SME/Large Enterprise status\***

\* (delete as appropriate)

**We also declare that:**

- a. We have read the Price Inquiry and appendices thereto, we raise no objections and we have obtained the information necessary to prepare our bid.
- b. Our bid price includes a lump sum that covers all the obligations of the future Seller as necessary to deliver the subject of this Price Inquiry.
- c. Our bid will remain valid and binding for 60 calendar days from the end date of the time limit for the submission of bids.
- d. We operate in accordance with the Pharmaceutical Law Act of 6 September 2001 (Journal of Laws of 2008 No. 45, item 271, as amended) and are not involved in the so-called reverse drug distribution chain.
- e. We represent that the following circumstances do not apply to us:
  1. as described in Article 7(1) of the Act of 13 April 2022 on Special Measures to Counteract Support for the Aggression against Ukraine and to Protect National Security;
  2. as described in Article 5k of the Council Regulation (EU) No 833/2014 of 31 July 2014 concerning restrictive measures in view of Russia's actions destabilising the situation in Ukraine.

.....  
(place and date)

.....  
(signature(s) of person(s) authorised to submit  
statements of will on behalf of the Bidder)